Vijay Maruti Patil
Overview
Explore the profile of Vijay Maruti Patil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Patil V, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, et al.
J Clin Oncol
. 2023 Jan;
41(13):2350-2361.
PMID: 36706347
Purpose: There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing chemoradiation. Docetaxel was assessed...
12.
Kanteti A, Ghose J, Patil V, Tamhankar A, Abraham G, Noronha V, et al.
Indian J Surg Oncol
. 2023 Jan;
13(4):789-796.
PMID: 36687234
Anaplastic thyroid carcinoma (ATC) is a rare thyroid malignancy with a dire prognosis, nearly 100% disease specific mortality and a median overall survival less than 6 months. In view of...
13.
Patil V, Noronha V, Prabhash K, Bhattacharjee A
J Clin Oncol
. 2023 Jan;
41(9):1791.
PMID: 36669137
No abstract available.
14.
Patil V, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al.
J Clin Oncol
. 2022 Oct;
41(2):222-232.
PMID: 36265101
Purpose: The regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their...
15.
Bondili S, Nandhana R, Dhanawat A, Noronha V, Joshi A, Patil V, et al.
Ecancermedicalscience
. 2022 Oct;
16:1438.
PMID: 36200011
Background: Pulmonary sarcomatoid carcinoma (PSC) constitutes a heterogeneous group of poorly differentiated non-small cell lung cancers. Since these are rare tumours, we sought to determine the characteristics and clinical outcomes...
16.
Lung cancer with dual and driver alterations at baseline: a retrospective observational cohort study
Noronha V, Chougule A, Chandrani P, Kaushal R, Patil V, Menon N, et al.
Acta Oncol
. 2022 Aug;
61(9):1143-1147.
PMID: 35972844
No abstract available.
17.
Noronha V, Patil V, Menon N, Prabhash K
J Clin Oncol
. 2022 Jun;
40(26):3095-3096.
PMID: 35709436
No abstract available.
18.
Behel V, Chougule A, Noronha V, Patil V, Menon N, Singh A, et al.
Clin Lung Cancer
. 2022 Jun;
23(5):410-418.
PMID: 35649817
Introduction: Plasma cfDNA-based mutation analysis has shown disease-monitoring potential in various cancers. We assessed the potential of cfDNA-based EGFR mutation testing as a monitoring tool in patients with NSCLC. Patients...
19.
Choudhary A, Abraham G, Patil V, Menon N, Mandal T, Jacob S, et al.
Indian J Surg Oncol
. 2022 Apr;
13(1):81-86.
PMID: 35462674
The real-world patterns of TKI use in differentiated thyroid cancer (DTC) are largely governed by the accessibility and financial feasibility of the patient with more sorafenib use compared to lenvatinib....
20.
Menon N, Noronha V, Patil V, Joshi A, Bhattacharjee A, Kalra D, et al.
Cancer Med
. 2022 Mar;
11(21):3939-3948.
PMID: 35343648
Introduction: This trial was conducted to compare the efficacy of low dose once-a-week cisplatin and once-every-3-weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). The...